GOG-3101 | TroFuse-20 Clinical Trial Update

In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer.

★ Support this podcast ★

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(19)

GOG-3073/ ENGOT-ov72/ APGOT-Ov10/ LACOG-0223/ ROSELLA FDA APPROVAL PODCAST

10 Heinä 9min

InnovaTV 205 GOG-3024/ENGOT-cx8 Publication Podcast

26 Kesä 11min

Uterine Cancer Awareness Month 2026 Podcast

26 Kesä 7min

Accrual Culture: Top Points for Site Selection - Timelines

The GOG Foundation, Inc. would like to thank our commercial supporters for their support of the GOG GYN-LIVE Podcast:Corcept Therapeutics, GSK, Pfizer Oncology, Eli Lilly, Genmab, and Verastem ★ Su...

2 Huhti 20min

Accrual Culture: Top Points for Site Selection - Responsiveness

6 Maalis 17min

The GOG Highlight Reel - January 2026

The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major me...

20 Helmi 2h 15min